Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392222 · ClinicalTrials.gov registry record
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 21
- Enrollment target
NCT01392222: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01392222 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01392222 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to understand more about why some patients choose to have surgery to treat their papillary microcarcinoma (PMC) and others choose to have their papillary microcarcinoma (PMC) regularly watched by their doctor to see if and when they may need surgery (referred to as "active surveillance"). The investigators also hope learn more about what patients and their family members worry about or feel they will gain from surgery or active surveillance.
Primary Outcome
We'll conduct focus groups \& individual interviews with 2 population segments established by the method of Krueger \& Casey \& Morgan. The population segments will be thyroid cancer patients who have had surg or have scheduled surg, \& any pt-designated significant others who assisted pts with tx decision-making \& thyroid cancer pts who chose to not have immediate surg, whether they are either postponing their tx decision until a later date, or have committed to active surveillance rather than
Interventions
- BEHAVIORAL Focus groups
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-06 |
What the finished NCT01392222 record still lists
NCT01392222 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Focus groups is the first listed.
NCT01392222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01392222 about?
NCT01392222 is a clinical study titled "Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others". The purpose of this study is to understand more about why some patients choose to have surgery to treat their papillary microcarcinoma (PMC) and others choose to have their papillary microcarcinoma (PMC) regularly watched by their doctor to see if and when they may need surgery (referred to as "acti...
What is the current status of trial NCT01392222?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2011-06. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01392222?
The interventions under investigation include: Focus groups (BEHAVIORAL).
Who is sponsoring clinical trial NCT01392222?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia